Taiwan TCMs Set To Hit Mainland Market
This article was originally published in PharmAsia News
Executive Summary
At a recent forum on cross-strait TCM cooperation and technology exchange, Xiamen Traditional Chinese Medicine signed a letter of intent for TCM industry collaboration with Taiwan's three pharmaceutical companies - Sun Ten Pharmaceutical, Sheng Chang Pharmaceutical and Chuang Song Zong Pharmaceutical. The China firm promises to use its marketing channels to bring Taiwan-made health products and TCM into the mainland market. In addition, Taiwan and China will leverage on Xiamen as a platform for TCM communication and will enhance cooperation on raw material purchases, herbal slice processing, herbal extract production, TCM formulation innovation, new drug development and establishing marketing channels. Both parties also reached an understanding on codeveloping TCM business opportunities in a global market. (Click here for more - Chinese Language)
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.